DNMT1 and myelodysplastic syndrome: Small molecule inhibitors targeting enzymes regulating DNA methylation are widely available, with azacitidine (AZA) and decitabine (DAC) being FDA-approved DNMT inhibitors (DNMTi) for treating myelodysplastic syndromes (MDS) [57].